Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.
Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
Practical Management of Adverse Events Associated With Cabozantinib Treatment in Patients With Renal-cell Carcinoma
[OncoTargets and Therapy] This research reviews the management of the more common adverse events associated with cabozantinib treatment for patients with patients with advanced clear-cell renal-cell carcinoma.
Although use of medical co-management and rehabilitation services increasing for older patients with kidney cancer, consultation remains sparse for those undergoing surgery.
Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).
Complete surgical metastasectomy correlated with increased survival in patients with metastatic renal cell carcinoma (mRCC) compared with incomplete surgical metastasectomy.
Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.
Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.
Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.
Alternating treatment with pazopanib and everolimus failed to prolong progression-free survival compared with continuous pazopanib.
Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection
[OncoTargets and Therapy] This research We reviews the development of cabozantinib in advanced renal cell carcinoma and its role in the treatment landscape.
A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.
Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis
[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.
A potential cancer therapy with a unique strategy to block the mTOR molecule has been designed. This new mTOR-inhibiting compound reduced the size of tumors resistant to earlier-generation mTOR inhibitors.
Several genetic differences uncovered in an analysis of data from The Cancer Genome Atlas (TCGA) are biologically plausible contributing factors for the worse survival of African American patients with clear cell renal carcinoma, even in the era of targeted therapy.
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Adjuvant treatment with sorafenib or sunitinib demonstrated no survival benefit in patients with resected local renal cell carcinoma at high risk for disease recurrence.
Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor Vaccine
In this study, researchers sought to characterize a panel of 36 tumor-associated antigens and cellular marker proteins from tumor material of 133 patients with renal cell carcinoma who underwent radical neprhectomy.
For smaller renal masses sized at 4 cm or less, mass biopsy is accurate.
Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.
Everolimus-induced stomatitis did not negatively affect progression-free survival in patients with various types of cancer, such as breast cancer and renal cell carcinoma.
Improvements to progression-free survival (PFS) seen across patient subgroups treated with cabozantinib.
This newly approved drug operates by targeting the PD-1/PD-L1 cellular pathway.
For patients with diabetes, poor glycemic control is linked to higher risk of postoperative progression.
The FDA extended indications for nivolumab (Opdivo) to include treatment of advanced (metastatic) renal cell carcinoma (RCC).
Genetic mutations in the REST gene have been shown to cause Wilms tumor, a rare kidney cancer that occurs in children. The findings identified mutations in the REST gene in 16 children with Wilms tumor.
Type 1 and type 2 carcinomas are characterized by specific genetic alterations; type 2 consists of at least three subtypes.
A recent study has linked an increased risk of kidney cancer to certain meat-cooking mutagens.
Independent risk factors for toxicity-related treatment discontinuation (TrTD) in patients with metastatic renal cell carcinoma (mRCC).
Frequent adverse events experienced by patients receiving tyrosine kinase inhibitors are hand-foot syndrome and mucositis/stomatitis.
Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years
Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma (RCC).
A new drug is proven more effective than standard therapies for advanced kidney cancer in patients with demonstrated drug resistance.
In new clinical trial, Nivolumab raised median survival for patients with advanced renal-cell carcinoma.
Four drugs that were recently approved by the FDA for the treatment of kidney cancer are being doubted for their clinical application.
Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for aggressive renal cell carcinoma (RCC).
Robotic Inferior Vena Cava (IVC) Thrombectomy Successfully Removes Thrombus Associated With Kidney Cancer
Inferior vena cava (IVC) thrombectomy is typically is performed via a large open incision, but recently the procedure was successfully performed robotically, using only seven small incisions.
The FDA has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma (RCC).
Patients with unilateral Wilms tumor who underwent unilateral radical nephrectomy appear to have low risk for renal dysfunction.
Surgeons successfully performed an inferior vena cava (IVC) thrombectomy robotically in nine patients with kidney cancer.
Children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
Head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of kidney cancers.
Two case studies have described what is believed to be the first reported successful use of stereotactic body radiation therapy for an oft-deadly kidney cancer complication.
A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.
Researchers developed a noninvasive urine test that screens for kidney cancer.
A higher intake of lycopene in postmenopausal women may decrease the risk for developing renal cell carcinoma.
Use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma.
In situations where small renal tumors confined to the kidneys, active monitoring, as opposed to immediate surgery, is associated with low rates of tumor growth or mortality.
In patients likely to have surgery, close monitoring of small renal tumors is associated with low rates of cancer growth or mortality.
A test that has the potential to improve treatment of patients with clear cell renal cell carcinoma (ccRCC).
Organ preservation in kidney cancer more likely at facilities that are early adopters of robotic surgery
Patients with operable kidney cancers were more likely to have a partial nephrectomy, which is the recommended treatment for localized tumors, when treated in hospitals that were early adopters of robotic surgery, according to a new study.
An international scientific collaboration has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer, providing new insights not only into this rare cancer but other types as well.
Needle-guided tumor destruction procedures offer near equivalent lengths of cancer control when compared with surgery for patients with small kidney cancer tumors.
Mutations in a gene that helps regulate when genes are switched on and off in cells have been found to cause rare cases of Wilms tumor, the most common kidney cancer occurring in children.
In an analysis of small molecules called metabolites, a research team identified an enzyme key to applying the brakes on tumor growth.
A novel robot-assisted surgery technique may help with removal to difficult to locate tumors.
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer.
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer.
People are often told to reduce their cholesterol to improve their health, but new research suggests that low cholesterol may increase kidney cancer patients' risk of dying from their disease.
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.
This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.
A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.
Although pazopanib and sunitinib are similarly effective in patients with metastatic renal-cell cancer, pazopanib is associated with better safety and quality of life, according to a study.
Surgery is often the first step in treating kidney cancer, and new data questions whether removing only the tumor is better than removing the entire kidney.
Using robotic ultrasound probes for identification of kidney tumors during robotic partial nephrectomy offered the advantage of surgeon autonomy compared with the use of laparoscopic ultrasound probes.
New study results show that partial kidney removal and energy-based techniques to destroy tumors are increasingly used to manage kidney disease. However, the patients most in need of kidney-sparing surgery are surprisingly still more likely to undergo total nephrectomy.
A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer. The immunoassay measured the levels of three potential biomarkers for kidney cancer.
Levels of three serum proteins are much higher in kidney cancer patients, lending a highly accurate diagnosis.
Animal studies have suggested that sunitinib may promote cancer growth and metastasis, but this does not appear to happen in humans.
A surgical technique known as intracorporeal cooling and extraction (ICE) may reduce the need for conventional open surgery in kidney cancer.
A new radioactive tracer agent can be used with PET/CT to accurately detect clear cell renal cell carcinomas, the most common type of kidney cancer.
Researchers looking at multiple different levels of changes in renal cell carcinoma are closer to determining how these tumors grow and survive.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Among patients with renal cell carcinoma, whites consistently have a survival advantage over blacks, regardless of patient or tumor characteristics or surgical treatment. These findings suggest the need for additional efforts to prolong the survival of all patients with kidney cancer.
Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery. The overall and cancer specific survival rates are similar for both approaches.
Laparoendoscopic single-site surgery (LESS) for removal of a cancerous kidney led to a less painful recovery than did traditional multiport laparoscopy.
Evidence points to a dose-response relation between radiation exposure of the pancreas and risk of diabetes in survivors of childhood cancers.
Levels of an enzyme already considered a risk factor for aggressive renal cell carcinoma may also indicate how well an mTOR inhibitor will work.
Adding pazopanib to lapatinib for inflammatory breast cancer produces greater toxicity than lapatinib alone with no significant clinical benefit.
Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)
Overall US cancer death rates have continued to decline since the early 1990s, but excess weight and lack of sufficient activity contribute to the increased incidence of many cancers.
The system for monitoring adverse events in oncology clinical trials is in urgent need of reform, say the authors of a recent commentary.
Results from three new studies are consistent with earlier findings that aspirin can reduce cancer risk and, in some cases, metastasis.
Combination therapy may be a promising treatment approach for patients with advanced melanoma who experience the abscopal effect.
Sorafenib, sunitinib, and pazopanib have been found to carry a heightened risk of fatal complications, but the incidence remains low overall.
For patients with renal masses, use of partial nephrectomy increased from 15.3 to 24.7 percent.
Inlyta has been approved by the FDA to treat advanced renal cell carcinoma in patients who haven't responded to another drug.
The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have twice as great a risk for diverse infection-related and unrelated cancers.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.
The Oncologic Drug Advisory Committee recommended that the FDA withdraw its approval of bevacizumab's indication for breast cancer.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|